Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study

Trial Profile

Phase II Efficacy and Safety of Taro Pharmaceuticals' Pro-Drug T2000 (1,3-Dimethoxymethyl-5,5-Diphenyl-Barbituric Acid) In Patients With Essential Tremor: A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose Escalation Study

Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2013

At a glance

  • Drugs T 2000 (Primary)
  • Indications Essential tremor
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Taro Pharmaceuticals USA
  • Most Recent Events

    • 26 Dec 2013 Last checked against ClinicalTrials.gov
    • 09 Jun 2011 Results presented at the 15th International Congress of Parkinson's Disease and Movement Disorders.
    • 24 Aug 2007 The expected completion date for this trial is now 1 Dec 2007.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top